US006274581B1

(12) **United States Patent**
Gross

(10) **Patent No.: US 6,274,581 B1**
(45) **Date of Patent: *Aug. 14, 2001**

(54) **BLOCKING INDUCTION OF TETRAHYDROBIOPTERIN TO BLOCK INDUCTION OF NITRIC OXIDE SYNTHESIS**

(75) Inventor: **Steven S. Gross**, New York, NY (US)

(73) Assignee: **Cornell Research Foundation, Inc.**, Ithaca, NY (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **08/063,067**

(22) Filed: **May 20, 1993**

Related U.S. Application Data

(63) Continuation of application No. 07/813,507, filed on Dec. 26, 1991, now abandoned.

(51) **Int. Cl.**[7] **A61K 31/495**; A61K 31/50
(52) **U.S. Cl.** **514/249**
(58) **Field of Search** 514/249

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,557,106		1/1971	Roch	544/260 X
4,282,217		8/1981	Baglioni et al. .	
4,670,438	*	6/1987	Austel et al.	514/249
4,701,455	*	10/1987	Nichol et al.	514/249
4,734,438		3/1988	Macri	514/653
5,002,944	*	3/1991	Spada	514/221
5,028,627		7/1991	Kilbourn et al. .	
5,059,712		10/1991	Griffith .	

FOREIGN PATENT DOCUMENTS

8404040	*	10/1984	(EP)	A61K/31/505
PCT/US90/ 05199		9/1990	(WO) .	

OTHER PUBLICATIONS

Rees et al 110 CA:112347q 1989.*

Salvemini et al. 115 CA 204139c 1991.*

Kwon et al 111 CA 230525 q 1989.*

Med Index 10th Ed #1227 & 7834.*

Collier, J., et al, Trends in Pharmacological Sciences Including Toxicological Sciences, Elsevier Science Publishers, Ltd., published in UK, 1989, front page and pp. 428–431.

Marletta, M.A., "Nitric oxide: biosynthesis and biological significance", name of publication unknown, Elsevier Science Publishers, Ltd. (UK), pp. 448–453 (1989).

Moncada, S., et al, Pharmacological Reviews 43(2):109–142 (1991).

Werner, E., et al, Biochem. J., 262:861–866(1989).

Stuehr, D.J. et al, Synthesis of Nitrogen Oxides from L–Arginine by Macrophage Cytosol: Requirement for Inducible and Constitutive Components, *Biochem, Biophys. Res. Commun.*, (1989) vol. 161, 420–426.

Stuehr, D.J. et al., Activated Murine Macrophages Secrete a Metabolite of Arginine with the Bioactivity of Endothelium–Derived Relaxing Factor and the Chemical Reactivity of Nitric Oxide, *J. Exp. Med.*, (1989) vol. 169, 1011–1020.

Rees, D.D. et al., Role of Endothelium–Derived Nitric Oxide in the Regulation of Blood Pressure, *Proc. Natl. Acad. Sci. U.S.A.*, (1989) vol. 86, 3375–3378.

Aisaka, K. et al., N^G–Methylarginine, An Inhibitor of Endothelium–Derived Nitric Oxide Synthesis, is a Potent Pressor Agent in the Guinea Pig: Does Nitric Oxide Regulate Blood Pressure in vivo, *Biochem. Biophys. Res. Commun.* (1989) 160:881–886.

Natanson, C. et al., Endotoxin and Tumor Necrosis Factor Challenges in Dogs Simulate the Cardiovascular Profile of Human Septic Shock, *Journal of Exp. Med.* (1989) 169:823–832.

Schmidt, H. et al., Arginine is a Physiological Precursor of Endothelium–Derived Nitric Oxide, *Eur. J. of Pharmacology* (1988) 154:213–216.

Palmer, R.M.J. et al., L–Arginine is the Physiological Precursor for the formation of Nitric Oxide in Endothelium–Dependent Relaxation, *Biochem. Biophys. Res. Commun.* (1988) 153:1251–1256.

Sakuma, I. et al., Identification of Arginine as a Precursor of Endothelium–Derived Relaxing Factor, *Proc. Natl. Acad. Sci U.S.A.* (1988) 85:8664–8667.

Palmer, R.M.J. et al., Vascular Endothelial Cells Synthesize Nitric Oxide from Arginine, *Nature*, (1988) vol. 333, 664–666.

Hibbs, J.B. et al., Nitric Oxide: A Cytotoxic Activated Macrophage Effector Molecule, *Biochem. Biophys. Res. Commun.* (1988) 157:87–94.

Marletta, M.A. et al., Macrophage Oxidation of L–Arginine to Nitrite and Nitrate: Nitric Oxide Is an Intermediate, *Biochemistry* (1988) 27:8706–8711.

Palmer, R.M.J. et al., Nitric Oxide Release Accounts for the Biological Activity of Endothelium–Derived Relaxing Factor, *Nature* (1987) 327:524–526.

Stuehr, D.J. et al., Induction of Nitrite/Nitrate Synthesis in Murine Macrophages by BCG Infection, Lymphokines, or Interferon–γ, *J. of Immunology* (1987) 139:518–525.

(List continued on next page.)

Primary Examiner—Russell Travers

(57) **ABSTRACT**

Guanosine triphosphate pathway tetrahydrobiopterin synthesis antagonist and/or pterin salvage pathway tetrahydrobiopterin synthesis antagonist are administered to inhibit nitric oxide synthesis from arginine in vascular smooth muscle cells in a subject in need of such inhibition (e.g. for prophylactic or curative effect for cytokine-induced hypotension or for restoration of vascular contractile sensitivity to pressor agents in the treatment of such hypotension).

12 Claims, 9 Drawing Sheets